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IMPACT OF DISEASE AND MOBILIZING AGENTS ON INITIAL AND RE-
MOBILIZATION FAILURE
DiPersio, J.F.1, Smith, A.2, Sempek, D.2, Baker, A.2, Jiang, S.3,
Vij, P.1, Cashen, A.1, Westervelt, P.1 1Washington University, St.
Louis, MO; 2Barnes-Jewish Hospital, St. Louis, MO; 3University of
British Columbia, Vancouver, BC, Canada.
Background: High-dose chemotherapy with autologous stem cell
transplantation (ASCT) is a common treatment strategy in lymphoma
and myeloma, but no standard approach for the mobilization of
peripheral hematologic stem and progenitor cells has been estab-
lished. Levels of circulating CD34 cells, a surrogate marker for
mobilization efﬁciency, vary widely between pts, and may be inﬂu-
enced by disease state, prior therapy, and/or mobilization regimen.
Methods: The Washington University (St. Louis, MO) transplanta-
tion database includes clinical parameters from 407 MM, 562 NHL,
and 164 HD pts who received an ASCT (1995-2006). A retrospective
analysis of this large (1133 pts) population was conducted to deter-
mine factors associated with mobilization efﬁciency. Mobilization
failure was deﬁned as collection of  2  10^6 CD34 cells/kg
within 5 apheresis days. Statistical analysis included ANOVA with
Scheffe Test to determine differences in mobilization between the
various mobilization regimens (G-CSF, G-CSF/chemotherapy, G-/
GM-CSF, G-CSF/AMD3100). Results: All pts were included in the
analysis; 87% received G-CSF alone as the initial mobilization regi-
men. Mobilization failure rates are summarized in Table 1. NHL and
HD pts had a 4-fold higher failure rate than MM pts. G-CSF/chemo
increased the median CD34 yield compared to G-CSF alone, al-
though no obvious impact on the failure rate was noted in this
relatively small group of pts. Remobilization was associated with high
failure rates inNHL (79.2%), HD (77.1%), andMM (73.3%). Pooled
collections were2 10^6 CD34/kg in 33.6%, 37.1%, and 36.7%
of failed mobilizers, resp. G-CSF mobilization failures remobilized
with G-CSF plus AMD3100 collected signiﬁcantly more CD34
cells than G-CSF-failures remobilized with either G-CSF, G/GM-
CSF or G-CSF/chemo (1-way ANOVA: F(3, 233)  27.878, F0.5(3,
233).05  2.643, p  .0001). The compared groups did not signiﬁ-
cantly differ in initial mobilization efﬁciency with G-CSF (as deter-
mined by ANOVA and Scheffe Test). Conclusions: The mobiliza-
tion failure rate is substantially higher in NHL and HD pts than MM
pts. Pts who fail initial mobilization are likely to fail a 2nd mobiliza-
tion, regardless of disease state. As the combination of chemotherapy
to G-CSF may not be sufﬁcient to reduce failure rates, alternative
mobilization strategies are needed to improve HSPC collection, par-
ticularly in NHL/HD pts and failed mobilizers.
First mobilization failures ( 210^6 CD34/kg)
Mobilization
regimen N Failures
Median
yield
(x10^6)
Median
yield
(x10^6)
NHL G-CSF 471 26.5% 2.89 2.76-3.04
G-CSF/Chemo 35 22.9% 4.68 2.8-8.53
All* 564 28.7%
HD G-CSF 130 26.2% 3.01 2.75-3.37
G-CSF/Chemo 12 16.7% 5.38 2.35-9.52
All* 165 24.8%
MM G-CSF 386 6.5% 4.62 4.16-4.98
G-CSF/Chemo 17 5.9% 8.52 4.46-16.3
All* 409 6.6%
*Incl. pts mobilized w. alternative regimens
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Introduction: Conditioning regimens for autologous stem cell
transplantation (ASCT) in patients with acute myeloid leukemia
(AML) using more speciﬁc drugs for myeloid malignancies, such as
high-dose Ara-C (HD/Ara-C) and etoposide, have been increas-
ingly proposed as an alternative the classic BUCY schedule. Ob-
jectives: To analize safety and efﬁcacy of a conditioning regimen
combining busulfan, etoposide, HD/Ara-C, and G-CSF priming
for patients with AML in ﬁrst complete remission (CR1) under-
going ASCT. Patients: 147 patients with AML in CR1 after
induction and consolidation therapy with idarubicin or daunoru-
bicin and Ara-C following a ‘37’ schedule (PETHEMA LMA99
trial) underwent ASCT. They were 65 male and 82 female with a
median age 46 years. The median WBC and platelet counts at
presentation were 2  109/L (range, 0.04-193) and 59  109/L
(range, 7-578), respectively. According to the MRC criteria, 125
patients with available karyotype (85%) were classiﬁed as follows:
24 patients (19%) with standard risk, 87 patients (70%) with
intermediate risk, and 14 patients (11%) with high risk. Condi-
tioning regimen consisted of busulfan 1 mg/kg/6 hours on days -8
to -5, etoposide 20 mg/kg/day on days -4 and -3, Ara-C 3 g/m2/12
hours on days -3 and -2, and G-CSF 10 g/kg/day on days -9 to -2.
Results: Median time from diagnosis to ASCT was 6 months.
Median time to neutrophil count recovery above 0.5  109/L was
12 days (range, 5-90) and days of hospital stay was 29 days (range,
11-94). Thirty-two percent of patients had bacteremia, 9.5% doc-
umented infection without bacteremia , and 21% clinically docu-
mented infection without microbiological documentation. The
most relevant extrahematological toxicity was gastrointestinal tox-
icity grade 3 (36%). Event-free survival (EFS) at 4 years was
53%. Cytogenetics was the only variable associated to EFS: 62%
for standard-risk group, 52% for intermediate-risk group, and 24%
for high-risk group (P  0.0066). Five patients died due to ASCT
(transplant-related mortality, 3.4%). Four of them died before day
100 mainly due to infections, while the remaining patient died of
pulmonary thromboembolism 31 months after ASCT. Conclu-
sions: The conditioning regimen combining busulfan, etoposide,
HD/Ara-C, and G-CSF priming shows a high antileukemic efﬁ-
cacy in patients with AML in CR1. This regimen shows a moderate
toxicity proﬁle and low transplant-related mortality. Citogenetics
was the only prognostic factor identiﬁed for EFS.
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ARSENIC TRIOXIDE WITH ASCORBIC ACID AND HIGH-DOSE MELPHA-
LAN FOR AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTA-
TION FOR MULTIPLE MYELOMA
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Couriel, D.P.1, Kebriaei, P.1, Popat, U.1, Alousi, A.M.1, De Lima, M.1,
Champlin, R.E.1, Giralt, S.A.1 1University of Texas - MD Anderson
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Backround: Arsenic trioxide (ATO) has been shown to be syner-
gistic with melphalan both in vitro and in vivo.We conducted a phase
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